24/7 Wall Street
08 Jul 2026, 12:42 UTC · 2h ago
This $1,200 Stock Could Be the Next Massive Stock Split Opportunity
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
08 Jul 2026, 12:42 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Eli Lilly raised its full-year 2026 revenue guidance to a range of $82 billion to $85 billion and increased its non-GAAP EPS guidance to $35.50–$37.00. — Upward revisions to both top and bottom-line guidance are primary catalysts for stock price appreciation.
+0.80Mounjaro generated $8.662 billion in Q1 2026, representing a 125% year-over-year increase. — Triple-digit growth in a flagship product validates the core growth thesis and suggests strong market demand.
+0.70Four board directors purchased shares at progressively higher prices between April and June 2026, with prices ranging from $919.90 to $1,129.35. — Consistent insider buying at rising price levels signals high confidence in future upside from company leadership.
+0.60Continue reading
6 related stories
Search tags
The U.S. FDA approved Foundayo, a GLP-1 pill with no food or water restrictions, broadening the company's incretin offering. — New product approvals expand the addressable market and provide a competitive advantage in the GLP-1 space.
+0.50Eli Lilly announced four acquisitions in Q1 2026, targeting cell therapies, sleep-wake disorders, in vivo CAR-T, and myelofibrosis. — Aggressive M&A activity diversifies the pipeline beyond GLP-1s, reducing long-term single-product risk.
+0.40Which stocks this story touches
Exceptional revenue growth from Mounjaro and Zepbound, strong earnings beats, and raised full-year guidance.
Mentioned only as a historical reference for an analyst's past success.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
30m ago
